Cargando…
Inhibiting Arginine Methylation as a Tool to Investigate Cross-Talk with Methylation and Acetylation Post-Translational Modifications in a Glioblastoma Cell Line
Glioblastomas (GBM) are the most common grade 4 brain tumours; patients have very poor prognosis with an average survival of 15 months after diagnosis. Novel research lines have begun to explore aberrant protein arginine methylation (ArgMe) as a possible therapeutic target in GBM and ArgMe inhibitor...
Autores principales: | Samuel, Sabrina Francesca, Marsden, Alistair James, Deepak, Srihari, Rivero, Francisco, Greenman, John, Beltran-Alvarez, Pedro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313862/ https://www.ncbi.nlm.nih.gov/pubmed/30347783 http://dx.doi.org/10.3390/proteomes6040044 |
Ejemplares similares
-
Arginine methylation: the promise of a ‘silver bullet’ for brain tumours?
por: Samuel, Sabrina F., et al.
Publicado: (2021) -
Love is in the hair: arginine methylation of human hair proteins as novel cardiovascular biomarkers
por: Marsden, Alistair James, et al.
Publicado: (2021) -
The Role of Protein Arginine Methylation as Post-Translational Modification on Actin Cytoskeletal Components in Neuronal Structure and Function
por: Qualmann, Britta, et al.
Publicado: (2021) -
Protein Arginine Methylation: An Emerging Modification in Cancer Immunity and Immunotherapy
por: Dai, Weijing, et al.
Publicado: (2022) -
Interaction modulation through arrays of clustered methyl-arginine protein modifications
por: Woodsmith, Jonathan, et al.
Publicado: (2018)